Evidence map›Paper›PMID 37720201›Full record

ArticleThe Journal of clinical and aesthetic dermatology2023

Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne.

Jerry Tan, Zoe D Draelos, Melinda J Gooderham, Andrew F Alexis, Emmy Graber, Jonette Keri, Heather C Woolery-Lloyd, Julie C Harper, Fran E Cook-Bolden, Adarsh Konda and 1 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jerry TanDr. Tan is with the Schulich School of Medicine and Dentistry at Western University in Ontario, Canada.
Zoe D DraelosDr. Draelos is with Dermatology Consulting Services, PLLC in High Point, North Carolina.
Melinda J GooderhamDr. Gooderham is with Queens University in Ontario, Canada and SKiN Centre for Dermatology and Probity Medical Research in Ontario, Canada.
Andrew F AlexisDrs. Alexis and Cook-Bolden are with Weill Cornell Medical College in New York, New York.
Emmy GraberDr. Graber is with The Dermatology Institute of Boston in Boston, Massachusetts and Northeastern University in Boston, Massachusetts.
Jonette KeriDrs. Keri and Woolery-Lloyd are with the University of Miami's Miller School of Medicine in Miami, Florida.
Heather C Woolery-LloydDrs. Keri and Woolery-Lloyd are with the University of Miami's Miller School of Medicine in Miami, Florida.
Julie C HarperDr. Harper is with the Dermatology and Skin Care Center of Birmingham in Birmingham, Alabama.
Fran E Cook-BoldenDrs. Alexis and Cook-Bolden are with Weill Cornell Medical College in New York, New York.
Adarsh KondaDr. Konda is with Ortho Dermatologics, a division of Bausch Health US, LCC, in Bridgewater, New Jersey.
Emil A TanghettiDr. Tanghetti is with the Center for Dermatology and Laser Surgery in Sacramento, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The condition of the skin can vary due to weather fluctuations. Therefore, this Methods: In two Phase III, double-blind, 12-week studies, participants aged nine years or older with moderate-to-severe acne were randomized 1:1 to once-daily tazarotene or vehicle lotion. The pooled population (N=1,614) was stratified by randomization date (warmer=May to September; colder=October to April). Evaluations included inflammatory/noninflammatory lesion counts, treatment success, adverse events, and safety/tolerability. Results: Tazarotene 0.045% lotion was similarly efficacious over colder and warmer months. Compared with vehicle, tazarotene demonstrated significantly greater least-squares mean absolute reductions from baseline to Week 12 in inflammatory (colder/warmer tazarotene vs. vehicle: -16.6/-15.8 vs. -13.2/-12.9) and noninflammatory lesions (-23.2/-22.6 vs. -17.5/-15.1); treatment success rates were also significantly higher (30.1/30.8% vs. 18.2/17.6%) ( Limitations: Geographical variation across study sites can lead to varying temperatures and humidity within the same months. Conclusion: Tazarotene 0.045% lotion was efficacious and well tolerated for acne treatment, regardless of season. Year-round tolerability of tazarotene 0.045% lotion may be due to its lower tazarotene concentration and polymeric emulsion technology, which simultaneously delivers moisturizers/humectants/emollients to skin.

Indexed as

acneRetinoidseasontolerabilityweather

Identifiers

PMID37720201
PMCPMC10503937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.